financial post
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
Financial Post • 3 MONTHS AGO
Ascent AeroSystems’ SPIRIT™ Joins Blue UAS Framework as a Cleared Component, Building on Its Status as a Blue UAS-Cleared System
Financial Post • 3 MONTHS AGO
Fortis Inc. Announces Pricing of Fixed-to-Fixed Rate Subordinated Notes
Financial Post • 3 MONTHS AGO
Savoring Summer: Enjoy an Extended Vacation in The Bahamas this September
Financial Post • 3 MONTHS AGO
Scientists Assail ‘Cherry-Picking’ of Trump Administration Climate Report
Financial Post • 3 MONTHS AGO
Google avoids breakup but faces other sanctions in monopoly case ruling
Financial Post • 3 MONTHS AGO
Ola Brynhildsen returns to Norway after loan stay with Toronto FC mutually terminated
Financial Post • 3 MONTHS AGO